NASDAQ:AQB - Nasdaq - US03842K3095 - Common Stock - Currency: USD
0.65
0 (0%)
The current stock price of AQB is 0.65 USD. In the past month the price increased by 9.45%. In the past year, price decreased by -62.21%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
AquaBounty Technologies, Inc. engages in the provision of land-based aquaculture services. The company is headquartered in Harvard, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2017-01-09. The Company’s technology advances in fish breeding, genetics, and health and nutrition. The company locates its land-based recirculating aquaculture system farms close to key consumption markets, which are designed to prevent disease and to include multiple levels of fish containment to protect wild fish populations. Its land-based farms utilize Recirculating Aquaculture Systems, which are designed to prevent disease and include multiple levels of fish containment designed to protect wild fish populations. Recirculating Aquaculture Systems facilities provide water treatment technology, including the use of ozone, salt treatment and ultraviolet radiation to kill potential bacterial, fungal, or viral pathogens which might enter the system.
AQUABOUNTY TECHNOLOGIES
233 Ayer Road Suite 4, Suite 4
Harvard MASSACHUSETTS 01754 US
CEO: Sylvia A. Wulf
Employees: 104
Company Website: https://aquabounty.com/
Investor Relations: https://investors.aquabounty.com/
Phone: 19786486000
The current stock price of AQB is 0.65 USD.
The exchange symbol of AQUABOUNTY TECHNOLOGIES is AQB and it is listed on the Nasdaq exchange.
AQB stock is listed on the Nasdaq exchange.
8 analysts have analysed AQB and the average price target is 1.02 USD. This implies a price increase of 56.92% is expected in the next year compared to the current price of 0.65. Check the AQUABOUNTY TECHNOLOGIES stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AQUABOUNTY TECHNOLOGIES (AQB) has a market capitalization of 2.52M USD. This makes AQB a Nano Cap stock.
AQUABOUNTY TECHNOLOGIES (AQB) currently has 104 employees.
AQUABOUNTY TECHNOLOGIES (AQB) has a support level at 0.64 and a resistance level at 0.68. Check the full technical report for a detailed analysis of AQB support and resistance levels.
The Revenue of AQUABOUNTY TECHNOLOGIES (AQB) is expected to decline by -65.64% in the next year. Check the estimates tab for more information on the AQB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AQB does not pay a dividend.
AQUABOUNTY TECHNOLOGIES (AQB) will report earnings on 2025-05-13.
AQUABOUNTY TECHNOLOGIES (AQB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.54).
The outstanding short interest for AQUABOUNTY TECHNOLOGIES (AQB) is 3.44% of its float. Check the ownership tab for more information on the AQB short interest.
ChartMill assigns a technical rating of 1 / 10 to AQB. When comparing the yearly performance of all stocks, AQB is a bad performer in the overall market: 87.85% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to AQB. AQB has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months AQB reported a non-GAAP Earnings per Share(EPS) of -7.54. The EPS decreased by -10.88% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -62.4% | ||
ROE | -73.45% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 45% to AQB. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -136.44% and a revenue growth -65.64% for AQB